Compare NBIX & WSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | WSO |
|---|---|---|
| Founded | 1992 | 1945 |
| Country | United States | United States |
| Employees | N/A | 7050 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.9B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | WSO |
|---|---|---|
| Price | $163.88 | $371.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | $180.91 | ★ $399.00 |
| AVG Volume (30 Days) | ★ 1.1M | 306.3K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $3.02 |
| Revenue Next Year | $13.14 | $5.20 |
| P/E Ratio | $87.58 | ★ $34.24 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $323.05 |
| 52 Week High | $169.57 | $494.94 |
| Indicator | NBIX | WSO |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 37.42 |
| Support Level | $134.92 | $355.10 |
| Resistance Level | N/A | $388.96 |
| Average True Range (ATR) | 4.51 | 11.59 |
| MACD | 0.13 | -1.65 |
| Stochastic Oscillator | 67.18 | 26.52 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Watsco is the largest HVAC and refrigeration products distributor in North America with approximately 13% market share. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada, Latin America, and the Caribbean. The company's customer base comprises more than 120,000 dealers and contractors serving the replacement and new-construction HVAC/R markets for residential and light-commercial applications. As much as 20% of residential HVAC units are distributed through Watsco in any given year. Revenue is approximately 75%-80% residential HVAC and 20%-25% commercial, with relatively small exposure to more complex "applied" solutions.